{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T19:54:35Z","timestamp":1793390075819,"version":"4.5.0"},"reference-count":111,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","license":[{"start":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T00:00:00Z","timestamp":1769126400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"2023 Yongzhou Guiding Science and Technology Program Projects","award":["2023YZ074"],"award-info":[{"award-number":["2023YZ074"]}]},{"name":"2023 Yongzhou Guiding Science and Technology Program Projects","award":["2023YZ092"],"award-info":[{"award-number":["2023YZ092"]}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,1,23]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Ankylosing spondylitis (AS) is a chronic inflammatory disease characterized by pain and stiffness in the spine and sacroiliac joints. It significantly reduces quality of life and imposes substantial social and economic burdens. Advances in understanding AS have led to the development of biological therapies, including tumor necrosis factor-\u03b1 inhibitors, interleukin-17 inhibitors, and Janus kinase (JAK) inhibitors, which show promise in managing symptoms and improving patient outcomes. This study aims to explore the overall research trends and future directions in this field using bibliometric methods.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>This study conducted a bibliometric analysis of research on biological therapies for AS from 2004 to 2024. We searched the Web of Science Core Collection and PubMed databases for relevant studies and used tools such as Microsoft Excel, CiteSpace, and VOSviewer to analyze publication trends, citation patterns, and research hotspots. The analysis focused on identifying key research areas, influential publications, and emerging trends in the field.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Our findings revealed a significant increase in publications, citations, and scholarly involvement over the past 2 decades. The United States, China, and Germany were the leading countries in publication numbers. Key research areas included the efficacy of biological agents, personalized treatment strategies, and combination therapies. The most cited studies focused on the clinical impact of tumor necrosis factor-\u03b1 inhibitors, interleukin-17 inhibitors, and emerging therapies such as Janus kinase inhibitors. Future research is expected to explore dual-target biologics, new cytokine pathways, gene therapy, and the impact of biological therapies on the gut microbiota.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>This bibliometric analysis highlights the growing interest in biological therapies for AS, identifying research gaps and future directions to enhance treatment and improve patient outcomes. The findings underscore the need for further research on the long-term efficacy and safety of biological agents and the development of personalized and combination therapies to address the complex challenges posed by AS.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/md.0000000000044201","type":"journal-article","created":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T18:01:09Z","timestamp":1769191269000},"page":"e44201","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":3,"title":["Current status and emerging trends in biological therapies for ankylosing spondylitis: A bibliometric analysis (2004\u20132024)"],"prefix":"10.1097","volume":"105","author":[{"given":"Rong","family":"Deng","sequence":"first","affiliation":[{"name":"Department of Orthopedics and Traumatology, Yongzhou Hospital of Traditional Chinese Medicine, Yongzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuan","family":"Jiang","sequence":"additional","affiliation":[{"name":"Department of Orthopedics and Traumatology, Yongzhou Hospital of Traditional Chinese Medicine, Yongzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin-xin","family":"Zhong","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Yongzhou Hospital of Traditional Chinese Medicine, Yongzhou, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fu","family":"Shen","sequence":"additional","affiliation":[{"name":"Department of Orthopedics and Traumatology, Yongzhou Hospital of Traditional Chinese Medicine, Yongzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Qian","sequence":"additional","affiliation":[{"name":"Department of Orthopedics and Traumatology, Yongzhou Hospital of Traditional Chinese Medicine, Yongzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-4538-9418","authenticated-orcid":false,"given":"Chang-wen","family":"Quan","sequence":"additional","affiliation":[{"name":"Department of Orthopedics and Traumatology, Yongzhou Hospital of Traditional Chinese Medicine, Yongzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20260610","first-page":"52","article-title":"The effects of pre-obesity on quality of life, disease activity, and functional status in patients with ankylosing spondylitis.","volume":"4","author":"Toy","year":"2017","journal-title":"North Clin Istanb"},{"key":"R2-20260610","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.2147\/PPA.S324097","article-title":"Predictors of health-related quality of life in patients with ankylosing spondylitis in Southwest China.","volume":"15","author":"Song","year":"2021","journal-title":"Patient Preference Adherence"},{"key":"R3-20260610","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s42358-019-0051-2","article-title":"Effect of food intake and ambient air pollution exposure on ankylosing spondylitis disease activity.","volume":"59","author":"Soleimanifar","year":"2019","journal-title":"Adv Rheumatol"},{"key":"R4-20260610","doi-asserted-by":"crossref","first-page":"2171475","DOI":"10.1155\/2019\/2171475","article-title":"Improvement of disease management and cost effectiveness in Chinese patients with ankylosing spondylitis using a smart-phone management system: a prospective cohort study.","volume":"2019","author":"Ji","year":"2019","journal-title":"Biomed Res Int"},{"key":"R5-20260610","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1586\/14737167.2014.957679","article-title":"Health-related quality of life in patients with ankylosing spondylitis: a comprehensive review.","volume":"14","author":"Kotsis","year":"2014","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"R6-20260610","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1111\/1756-185X.14070","article-title":"Evaluation of an ankylosing spondylitis education and self-management program: beneficial effects on ankylosing spondylitis specific outcomes.","volume":"24","author":"Inderjeeth","year":"2021","journal-title":"Int J Rheum Dis"},{"key":"R7-20260610","doi-asserted-by":"crossref","first-page":"602334","DOI":"10.3389\/fpubh.2020.602334","article-title":"Cost of illness, quality of life, and work outcomes in active ankylosing spondylitis patients treated with adalimumab in China.","volume":"8","author":"Tu","year":"2020","journal-title":"Front Public Health"},{"key":"R8-20260610","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1186\/s13075-018-1784-8","article-title":"Factors related to health-related quality of life in ankylosing spondylitis, overall and stratified by sex.","volume":"20","author":"Law","year":"2018","journal-title":"Arthritis Res Ther"},{"key":"R9-20260610","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1007\/s40744-023-00536-2","article-title":"Effect of upadacitinib on disease activity, pain, fatigue, function, health-related quality of life and work productivity for biologic refractory ankylosing spondylitis.","volume":"10","author":"Navarro-Compan","year":"2023","journal-title":"Rheumatol Ther"},{"key":"R10-20260610","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1002\/art.41164","article-title":"Nonsteroidal antiinflammatory drugs as potential disease-modifying medications in axial spondyloarthritis.","volume":"72","author":"Wang","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"R11-20260610","first-page":"1759720X","article-title":"Conventional disease-modifying antirheumatic drugs therapy may not slow spinal radiographic progression in ankylosing spondylitis: results from an 18-year longitudinal dataset.","volume":"12","author":"Lee","year":"2020","journal-title":"Ther Adv Musculoskel"},{"key":"R12-20260610","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s11926-017-0644-x","article-title":"The paradox of bone formation and bone loss in ankylosing spondylitis: evolving new concepts of bone formation and future trends in management.","volume":"19","author":"Magrey","year":"2017","journal-title":"Curr Rheumatol Rep"},{"key":"R13-20260610","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1177\/2040622317743486","article-title":"New advances in the understanding and treatment of axial spondyloarthritis: from chance to choice.","volume":"9","author":"Dubash","year":"2018","journal-title":"Ther Adv Chronic Dis"},{"key":"R14-20260610","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1007\/s40265-018-0971-x","article-title":"Beyond the TNF-alpha Inhibitors: new and emerging targeted therapies for patients with axial spondyloarthritis and their relation to pathophysiology.","volume":"78","author":"Pedersen","year":"2018","journal-title":"Drugs"},{"key":"R15-20260610","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1007\/s40259-020-00442-x","article-title":"Drug survival of biologics in treating ankylosing spondylitis: a systematic review and meta-analysis of real-world evidence.","volume":"34","author":"Yu","year":"2020","journal-title":"Biodrugs"},{"key":"R16-20260610","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1007\/s12672-025-01790-2","article-title":"Bibliometric analysis of glycolysis and prostate cancer research from 2004 to 2024.","volume":"16","author":"Zhu","year":"2025","journal-title":"Discov Oncol"},{"key":"R17-20260610","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1136\/ard.2010.138594","article-title":"Ankylosing Spondylitis Disease Activity Score (ASDAS): defining cut-off values for disease activity states and improvement scores.","volume":"70","author":"Machado","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"R18-20260610","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1016\/S0140-6736(13)61134-4","article-title":"Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial.","volume":"382","author":"Baeten","year":"2013","journal-title":"Lancet"},{"key":"R19-20260610","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1002\/art.41042","article-title":"2019 Update of the American College of Rheumatology\/Spondylitis Association of America\/spondyloarthritis research and treatment network recommendations for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis.","volume":"71","author":"Ward","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"R20-20260610","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1136\/annrheumdis-2016-210770","article-title":"2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis.","volume":"76","author":"van der Heijde","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"R21-20260610","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S0140-6736(16)31591-4","article-title":"Axial spondyloarthritis.","volume":"390","author":"Sieper","year":"2017","journal-title":"Lancet"},{"key":"R22-20260610","first-page":"CD005468","article-title":"TNF-alpha inhibitors for ankylosing spondylitis.","volume":"2015","author":"Maxwell","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"key":"R23-20260610","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1377\/hlthaff.2014.1023","article-title":"The evolution of biotechnology and its impact on health care.","volume":"34","author":"Evens","year":"2015","journal-title":"Health affairs (Project Hope)"},{"key":"R24-20260610","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1007\/s11926-020-00934-3","article-title":"Is axial spondyloarthritis more common than rheumatoid arthritis?","volume":"22","author":"Akkoc","year":"2020","journal-title":"Curr Rheumatol Rep"},{"key":"R25-20260610","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1007\/s40744-024-00685-y","article-title":"Comparative efficacy of advanced therapies in the treatment of radiographic axial spondyloarthritis or ankylosing spondylitis as evaluated by the ASDAS low disease activity criteria.","volume":"11","author":"Baraliakos","year":"2024","journal-title":"Rheumatol Ther"},{"key":"R26-20260610","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1007\/s10067-010-1647-4","article-title":"Increased serum IL-17 and IL-23 in the patient with ankylosing spondylitis.","volume":"30","author":"Mei","year":"2011","journal-title":"Clin Rheumatol"},{"key":"R27-20260610","first-page":"3493","article-title":"New insights into IL-17\/IL-23 signaling in ankylosing spondylitis (Review).","volume":"20","author":"Chisalau","year":"2020","journal-title":"Exp Ther Med"},{"key":"R28-20260610","doi-asserted-by":"crossref","first-page":"15645","DOI":"10.1038\/s41598-018-34026-1","article-title":"Inhibiting ex-vivo Th17 responses in ankylosing Spondylitis by targeting Janus kinases.","volume":"8","author":"Hammitzsch","year":"2018","journal-title":"Sci Rep"},{"key":"R29-20260610","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1002\/acr.23233","article-title":"Secukinumab and sustained improvement in signs and symptoms of patients with active ankylosing spondylitis through two years: results from a phase III study.","volume":"69","author":"Marzo-Ortega","year":"2017","journal-title":"Arthritis Care Res"},{"key":"R30-20260610","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1136\/annrheumdis-2019-216118","article-title":"Efficacy and safety of ixekizumab through 52 weeks in two phase 3, randomised, controlled clinical trials in patients with active radiographic axial spondyloarthritis (COAST-V and COAST-W).","volume":"79","author":"Dougados","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"R31-20260610","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1080\/14397595.2018.1538004","article-title":"Efficacy and safety of secukinumab in Japanese patients with active ankylosing spondylitis: 24-week results from an open-label phase 3 study (MEASURE 2-J).","volume":"30","author":"Kishimoto","year":"2020","journal-title":"Mod Rheumatol"},{"key":"R32-20260610","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s40744-020-00254-z","article-title":"Ixekizumab improves patient-reported outcomes in non-radiographic axial spondyloarthritis: results from the coast-X Trial.","volume":"8","author":"Deodhar","year":"2021","journal-title":"Rheumatol Ther"},{"key":"R33-20260610","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1136\/ard.2009.113696","article-title":"EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis.","volume":"69","author":"Peters","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"R34-20260610","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1093\/rheumatology\/kes066","article-title":"First update of the current evidence for the management of ankylosing spondylitis with non-pharmacological treatment and non-biologic drugs: a systematic literature review for the ASAS\/EULAR management recommendations in ankylosing spondylitis.","volume":"51","author":"van den Berg","year":"2012","journal-title":"Rheumatology (Oxford, England)"},{"key":"R35-20260610","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1007\/s10067-014-2660-9","article-title":"Update on the American College of Rheumatology\/Spondyloarthritis Research and Treatment Network\/Spondylitis Association of America axial spondyloarhtritis treatment guidelines project.","volume":"33","author":"Ward","year":"2014","journal-title":"Clin Rheumatol"},{"key":"R36-20260610","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1136\/annrheumdis-2016-209775","article-title":"EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015\/2016 update.","volume":"76","author":"Agca","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"R37-20260610","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.jbspin.2018.10.002","article-title":"Update of French society for rheumatology recommendations for managing rheumatoid arthritis.","volume":"86","author":"Daien","year":"2019","journal-title":"Joint Bone Spine"},{"key":"R38-20260610","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1136\/annrheumdis-2014-205322","article-title":"Efficacy of TNFalpha blockers in patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis: a meta-analysis.","volume":"74","author":"Callhoff","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"R39-20260610","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta20090","article-title":"Tumour necrosis factor-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis: a systematic review and economic evaluation.","volume":"20","author":"Corbett","year":"2016","journal-title":"Health Technol Asses"},{"key":"R40-20260610","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.cyto.2016.08.014","article-title":"Molecular mechanisms of action of anti-TNF-alpha agents - Comparison among therapeutic TNF-alpha antagonists.","volume":"101","author":"Mitoma","year":"2018","journal-title":"Cytokine"},{"key":"R41-20260610","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1080\/14397595.2018.1525017","article-title":"Effect of anti-tumor necrosis factor alpha treatment on radiographic progression in patient with ankylosing spondylitis: a systematic review and meta-analysis.","volume":"29","author":"Zong","year":"2019","journal-title":"Mod Rheumatol"},{"key":"R42-20260610","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1002\/jcph.1348","article-title":"The safety profile of tumor necrosis factor inhibitors in ankylosing spondylitis: are TNF inhibitors safer than we thought?","volume":"59","author":"Wronski","year":"2019","journal-title":"J Clin Pharmacol"},{"key":"R43-20260610","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1007\/s11926-022-01084-4","article-title":"Inhibiting IL-17A and IL-17F in rheumatic disease: therapeutics help to elucidate disease mechanisms.","volume":"24","author":"Tam","year":"2022","journal-title":"Curr Rheumatol Rep"},{"key":"R44-20260610","doi-asserted-by":"crossref","first-page":"141","DOI":"10.2147\/ITT.S259126","article-title":"Anti-IL-17 agents in the treatment of axial spondyloarthritis.","volume":"10","author":"Atzeni","year":"2021","journal-title":"Immunotargets Ther"},{"key":"R45-20260610","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1136\/annrheumdis-2020-219406","article-title":"Efficacy and safety of brodalumab, an anti-IL17RA monoclonal antibody, in patients with axial spondyloarthritis: 16-week results from a randomised, placebo-controlled, phase 3 trial.","volume":"80","author":"Wei","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"R46-20260610","doi-asserted-by":"crossref","first-page":"3053","DOI":"10.1007\/s10067-020-05545-y","article-title":"Efficacy and safety of interleukin-17A inhibitors in patients with ankylosing spondylitis: a systematic review and meta-analysis of randomized controlled trials.","volume":"40","author":"Wang","year":"2021","journal-title":"Clin Rheumatol"},{"key":"R47-20260610","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1159\/000525627","article-title":"Comparative efficacy and safety of janus kinase inhibitors and secukinumab in patients with active ankylosing spondylitis: a systematic review and meta-analysis.","volume":"107","author":"Lee","year":"2022","journal-title":"Pharmacology"},{"key":"R48-20260610","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.ejim.2022.04.007","article-title":"Efficacy and safety of Janus kinase inhibitors in patients with ankylosing spondylitis: a systematic review and meta-analysis.","volume":"102","author":"Li","year":"2022","journal-title":"Eur J Intern Med"},{"key":"R49-20260610","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1093\/rheumatology\/keab543","article-title":"Impact of filgotinib on sacroiliac joint magnetic resonance imaging structural lesions at 12 weeks in patients with active ankylosing spondylitis (TORTUGA trial).","volume":"61","author":"Maksymowych","year":"2022","journal-title":"Rheumatology"},{"key":"R50-20260610","doi-asserted-by":"crossref","first-page":"e222312","DOI":"10.1001\/jamanetworkopen.2022.2312","article-title":"Predicting probability of response to tumor necrosis factor inhibitors for individual patients with ankylosing spondylitis.","volume":"5","author":"Wang","year":"2022","journal-title":"Jama Netw Open"},{"key":"R51-20260610","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1038\/s41584-020-00540-8","article-title":"Immunogenicity of biologic agents in rheumatology.","volume":"17","author":"Strand","year":"2021","journal-title":"Nat Rev Rheumatol"},{"key":"R52-20260610","doi-asserted-by":"crossref","first-page":"e26823","DOI":"10.2196\/26823","article-title":"Predicting biologic therapy outcome of patients with spondyloarthritis: joint models for longitudinal and survival analysis.","volume":"9","author":"Barata","year":"2021","journal-title":"JMIR Med Inform"},{"key":"R53-20260610","first-page":"56","article-title":"Differences in biologics for treating ankylosing spondylitis: the contribution of network meta-analysis.","volume":"25","author":"Migliore","year":"2021","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"R54-20260610","doi-asserted-by":"crossref","first-page":"151996","DOI":"10.1016\/j.semarthrit.2022.151996","article-title":"Impact of biologics on health-related quality of life in patients with Ankylosing spondylitis: a systematic review and meta-analysis of randomized controlled trials.","volume":"54","author":"Ho","year":"2022","journal-title":"Semin Arthritis Rheu"},{"key":"R55-20260610","doi-asserted-by":"crossref","first-page":"2452","DOI":"10.3390\/jcm12072452","article-title":"Recent advances in the optimization of Anti-TNF treatment in patients with inflammatory bowel disease.","volume":"12","author":"Orfanoudaki","year":"2023","journal-title":"J Clin Med"},{"key":"R56-20260610","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s00393-020-00948-3","article-title":"Janus kinase inhibitors for treating active ankylosing spondylitis: a meta-analysis of randomized controlled trials.","volume":"81","author":"Lee","year":"2022","journal-title":"Z Rheumatol"},{"key":"R57-20260610","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1080\/1744666X.2020.1803063","article-title":"Ixekizumab for the treatment of ankylosing spondylitis.","volume":"16","author":"Huang","year":"2020","journal-title":"Expert Rev Clin Immunol"},{"key":"R58-20260610","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1007\/s10067-020-05342-7","article-title":"The effect of intravenous golimumab on health-related quality of life and work productivity in adult patients with active ankylosing spondylitis: results of the phase 3 GO-ALIVE trial.","volume":"40","author":"Reveille","year":"2021","journal-title":"Clin Rheumatol"},{"key":"R59-20260610","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1136\/ard.2010.137422","article-title":"Drug-specific risk of non-tuberculosis opportunistic infections in patients receiving anti-TNF therapy reported to the 3-year prospective French RATIO registry.","volume":"70","author":"Salmon-Ceron","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"R60-20260610","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1517\/14740338.2015.1009036","article-title":"Infection risk associated with anti-TNF-alpha agents: a review.","volume":"14","author":"Murdaca","year":"2015","journal-title":"Expert Opin Drug Saf"},{"key":"R61-20260610","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/s12032-009-9190-3","article-title":"TNF-alpha and its inhibitors in cancer.","volume":"27","author":"Zidi","year":"2010","journal-title":"Med Oncol"},{"key":"R62-20260610","first-page":"401","article-title":"Autoantibodies in psoriatic patients treated with anti-TNF-alpha therapy.","volume":"12","author":"Bardazzi","year":"2014","journal-title":"J Dtsch Dermatol Ges"},{"key":"R63-20260610","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1177\/0004563215604866","article-title":"Serum trough infliximab and anti-infliximab antibodies in a cohort of gastroenterology and rheumatology patients\u2019 infliximab therapeutic drug monitoring.","volume":"53","author":"Barlow","year":"2016","journal-title":"Ann Clin Biochem"},{"key":"R64-20260610","doi-asserted-by":"crossref","first-page":"e12760","DOI":"10.1111\/dth.12760","article-title":"Secondary failure of TNF-alpha inhibitors in clinical practice.","volume":"32","author":"Owczarczyk-Saczonek","year":"2019","journal-title":"Dermatol Ther"},{"key":"R65-20260610","doi-asserted-by":"crossref","first-page":"2534","DOI":"10.1056\/NEJMoa1505066","article-title":"Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis.","volume":"373","author":"Baeten","year":"2015","journal-title":"N Engl J Med"},{"key":"R66-20260610","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1007\/s40265-016-0602-3","article-title":"Secukinumab: a review in psoriatic arthritis.","volume":"76","author":"Shirley","year":"2016","journal-title":"Drugs"},{"key":"R67-20260610","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1038\/s41571-022-00600-w","article-title":"Immune-checkpoint inhibitors: long-term implications of toxicity.","volume":"19","author":"Johnson","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"key":"R68-20260610","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1111\/apt.15514","article-title":"Venous thromboembolic events in the tofacitinib ulcerative colitis clinical development programme.","volume":"50","author":"Sandborn","year":"2019","journal-title":"Alimentary Pharmacol Therap"},{"key":"R69-20260610","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1007\/s40266-020-00775-w","article-title":"Safety of janus kinase inhibitors in older patients: a focus on the thromboembolic risk.","volume":"37","author":"Rajasimhan","year":"2020","journal-title":"Drugs & aging"},{"key":"R70-20260610","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1007\/s40261-023-01260-z","article-title":"Safety of janus kinase inhibitors in patients with alopecia areata: a systematic review.","volume":"43","author":"Papierzewska","year":"2023","journal-title":"Clin Drug Invest"},{"key":"R71-20260610","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1186\/s42358-024-00402-x","article-title":"Integrated safety analysis of tofacitinib from Phase 2 and 3 trials of patients with ankylosing spondylitis.","volume":"64","author":"Deodhar","year":"2024","journal-title":"Adv Rheumatol"},{"key":"R72-20260610","doi-asserted-by":"crossref","first-page":"152461","DOI":"10.1016\/j.semarthrit.2024.152461","article-title":"Adverse cardiovascular events in rheumatoid arthritis patients treated with JAK inhibitors: an analysis of postmarketing spontaneous safety reports.","volume":"67","author":"Goldman","year":"2024","journal-title":"Semin Arthritis Rheum"},{"key":"R73-20260610","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1080\/13543784.2024.2351507","article-title":"Investigational bispecific antibodies for the treatment of rheumatoid arthritis.","volume":"33","author":"Venetsanopoulou","year":"2024","journal-title":"Expert Opin Investig Drugs"},{"key":"R74-20260610","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1007\/s40744-016-0038-y","article-title":"Network meta-analysis and cost per responder of tumor necrosis factor-\u03b1 and interleukin inhibitors in the treatment of active ankylosing spondylitis.","volume":"3","author":"Betts","year":"2016","journal-title":"Rheumatol Ther"},{"key":"R75-20260610","doi-asserted-by":"crossref","first-page":"669","DOI":"10.2217\/imt.15.28","article-title":"Biologics in spondyloarthritis: TNFalpha inhibitors and other agents.","volume":"7","author":"Toussirot","year":"2015","journal-title":"Immunotherapy"},{"key":"R76-20260610","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1007\/s10067-023-06540-9","article-title":"Knowledge mapping of biological disease-modifying anti-rheumatic drugs for axial spondyloarthritis: a bibliometric study.","volume":"42","author":"He","year":"2023","journal-title":"Clin Rheumatol"},{"key":"R77-20260610","doi-asserted-by":"crossref","first-page":"58","DOI":"10.2174\/1573397117666211012110212","article-title":"Associated factors with the severity of hip involvement in spondyloarthritis and efficacy of TNF alpha Inhibitors in these Patients.","volume":"18","author":"Slouma","year":"2022","journal-title":"Curr Rheumatol Rev"},{"key":"R78-20260610","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/s13075-022-02777-y","article-title":"The role of interleukin (IL)-23 in regulating pain in arthritis.","volume":"24","author":"Lee","year":"2022","journal-title":"Arthritis Res Ther"},{"key":"R79-20260610","first-page":"1759720X","article-title":"Secukinumab in axial spondyloarthritis: a narrative review of clinical evidence.","volume":"13","author":"Braun","year":"2021","journal-title":"Ther Adv Musculoskel"},{"key":"R80-20260610","doi-asserted-by":"crossref","first-page":"e0306792","DOI":"10.1371\/journal.pone.0306792","article-title":"Causal relationship between gut microbiota and ankylosing spondylitis and potential mediating role of inflammatory cytokines: a mendelian randomization study.","volume":"19","author":"Du","year":"2024","journal-title":"PLoS One"},{"key":"R81-20260610","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1038\/gt.2013.72","article-title":"Why commercialization of gene therapy stalled; examining the life cycles of gene therapy technologies.","volume":"21","author":"Ledley","year":"2014","journal-title":"Gene Ther"},{"key":"R82-20260610","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1089\/hum.2020.156","article-title":"Aspects of gene therapy products using current genome-editing technology in Japan.","volume":"31","author":"Yamaguchi","year":"2020","journal-title":"Hum Gene Ther"},{"key":"R83-20260610","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1007\/s00296-011-1994-8","article-title":"Susceptibility to ankylosing spondylitis: evidence for the role of ERAP1, TGFb1 and TLR9 gene polymorphisms.","volume":"32","author":"Wu","year":"2012","journal-title":"Rheumatol Int"},{"key":"R84-20260610","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.mehy.2012.10.003","article-title":"Association of ankylosing spondylitis with HLA-B27 and ERAP1: pathogenic role of antigenic peptide.","volume":"80","author":"Chen","year":"2013","journal-title":"Med Hypotheses"},{"key":"R85-20260610","doi-asserted-by":"crossref","first-page":"3132","DOI":"10.3389\/fimmu.2018.03132","article-title":"RUNX3 and T-Bet in immunopathogenesis of ankylosing spondylitis-novel targets for therapy?","volume":"9","author":"Vecellio","year":"2018","journal-title":"Front Immunol"},{"key":"R86-20260610","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1007\/s00296-022-05174-5","article-title":"The genetic backbone of ankylosing spondylitis: how knowledge of genetic susceptibility informs our understanding and management of disease.","volume":"42","author":"Kenyon","year":"2022","journal-title":"Rheumatol Int"},{"key":"R87-20260610","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1080\/14397595.2016.1206174","article-title":"New insights toward the pathogenesis of ankylosing spondylitis; genetic variations and epigenetic modifications.","volume":"27","author":"Mahmoudi","year":"2017","journal-title":"Mod Rheumatol"},{"key":"R88-20260610","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1038\/gene.2017.11","article-title":"Epigenetic and gene expression analysis of ankylosing spondylitis-associated loci implicate immune cells and the gut in the disease pathogenesis.","volume":"18","author":"Li","year":"2017","journal-title":"Genes Immun"},{"key":"R89-20260610","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1093\/postmj\/qgad073","article-title":"Impact of immune regulation and differentiation dysfunction of mesenchymal stem cells on the disease process in ankylosing spondylitis and prospective analysis of stem cell transplantation therapy.","volume":"99","author":"Feng","year":"2023","journal-title":"Postgrad Med J"},{"key":"R90-20260610","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1038\/s41419-020-02993-x","article-title":"Oxidative stress-mediated mitochondrial dysfunction facilitates mesenchymal stem cell senescence in ankylosing spondylitis.","volume":"11","author":"Ye","year":"2020","journal-title":"Cell Death Dis"},{"key":"R91-20260610","doi-asserted-by":"crossref","first-page":"103508","DOI":"10.1016\/j.scr.2024.103508","article-title":"Generation of induced pluripotent stem cells from an HLA-B27 positive ankylosing spondylitis patient with syndesmophyte formation.","volume":"80","author":"Tsai","year":"2024","journal-title":"Stem Cell Res"},{"key":"R92-20260610","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1177\/1078155220927750","article-title":"Coincident remission of ankylosing spondylitis after autologous stem cell transplantation for multiple myeloma.","volume":"27","author":"Shaikh","year":"2021","journal-title":"J Oncol Pharm Pract"},{"key":"R93-20260610","doi-asserted-by":"crossref","first-page":"11741","DOI":"10.2147\/JIR.S496991","article-title":"Influence of TNF-alpha inhibitors on gut microbiota and immune modulation in treating ankylosing spondylitis: insights into therapeutic mechanisms and clinical implications.","volume":"17","author":"Yuan","year":"2024","journal-title":"J Inflamm Res"},{"key":"R94-20260610","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1097\/FPC.0000000000000468","article-title":"Association of anti-TNF-alpha treatment with gut microbiota of patients with ankylosing spondylitis.","volume":"32","author":"Dai","year":"2022","journal-title":"Pharmacogenet Genom"},{"key":"R95-20260610","doi-asserted-by":"crossref","first-page":"e002794","DOI":"10.1136\/rmdopen-2022-002794","article-title":"Characterisation of gut microbiota composition in patients with axial spondyloarthritis and its modulation by TNF inhibitor treatment.","volume":"9","author":"Vallier","year":"2023","journal-title":"Rmd Open"},{"key":"R96-20260610","doi-asserted-by":"crossref","first-page":"111904","DOI":"10.1016\/j.biopha.2021.111904","article-title":"The influence of biologics on the microbiome in immune-mediated inflammatory diseases: a systematic review.","volume":"141","author":"Ruszkowski","year":"2021","journal-title":"Biomed Pharmacother"},{"key":"R97-20260610","doi-asserted-by":"crossref","first-page":"1154380","DOI":"10.3389\/fimmu.2023.1154380","article-title":"Alterations in the gut virome in patients with ankylosing spondylitis.","volume":"14","author":"Li","year":"2023","journal-title":"Front Immunol"},{"key":"R98-20260610","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1007\/s11926-012-0268-0","article-title":"Endoplasmic reticulum aminopeptidase 1 and interleukin-23 receptor in ankylosing spondylitis.","volume":"14","author":"Haroon","year":"2012","journal-title":"Curr Rheumatol Rep"},{"key":"R99-20260610","doi-asserted-by":"crossref","first-page":"2933","DOI":"10.3389\/fimmu.2018.02933","article-title":"Genetics and functional genomics of spondyloarthritis.","volume":"9","author":"Costantino","year":"2018","journal-title":"Front Immunol"},{"key":"R100-20260610","doi-asserted-by":"crossref","first-page":"151","DOI":"10.3390\/jpm10040151","article-title":"The genetics of spondyloarthritis.","volume":"10","author":"Diaz-Pena","year":"2020","journal-title":"J Pers Med"},{"key":"R101-20260610","doi-asserted-by":"crossref","first-page":"676","DOI":"10.3892\/etm.2021.10108","article-title":"Characteristics of the intestinal microbiome in ankylosing spondylitis.","volume":"22","author":"Cardoneanu","year":"2021","journal-title":"Exp Ther Med"},{"key":"R102-20260610","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1159\/000540271","article-title":"Effect of long-snake moxibustion on gut microbiota of patients with ankylosing spondylitis.","volume":"31","author":"Yu","year":"2024","journal-title":"Complement Med Res"},{"key":"R103-20260610","doi-asserted-by":"crossref","first-page":"2403935","DOI":"10.1155\/2018\/2403935","article-title":"Role of Interleukin- (IL-) 17 in the Pathogenesis and Targeted Therapies in Spondyloarthropathies.","volume":"2018","author":"Chyuan","year":"2018","journal-title":"Mediators Inflamm"},{"key":"R104-20260610","doi-asserted-by":"crossref","DOI":"10.1177\/1759720X211025894","article-title":"Immunomodulation with IL-17 and TNF-\u03b1 in spondyloarthritis: focus on the eye and the central nervous system.","volume":"13","author":"How Shing Koy","year":"2021","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"R105-20260610","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1093\/rheumatology\/ket260","article-title":"The role of DMARDs in reducing the immunogenicity of TNF inhibitors in chronic inflammatory diseases.","volume":"53","author":"Jani","year":"2014","journal-title":"Rheumatology (Oxford, England)"},{"key":"R106-20260610","doi-asserted-by":"crossref","first-page":"1005111","DOI":"10.1155\/2022\/1005111","article-title":"Gut microbiota and inflammatory cytokine changes in patients with ankylosing spondylitis.","volume":"2022","author":"Liu","year":"2022","journal-title":"Biomed Res Int"},{"key":"R107-20260610","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1038\/ng.2667","article-title":"Identification of multiple risk variants for ankylosing spondylitis through high-density genotyping of immune-related loci.","volume":"45","author":"Cortes","year":"2013","journal-title":"Nat Genet"},{"key":"R108-20260610","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.3899\/jrheum.160347","article-title":"Developing a risk-scoring model for ankylosing spondylitis based on a combination of HLA-B27, single-nucleotide polymorphism, and copy number variant markers.","volume":"43","author":"Jung","year":"2016","journal-title":"J Rheumatol"},{"key":"R109-20260610","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1186\/s12967-024-05925-x","article-title":"Identifying prioritization of therapeutic targets for ankylosing spondylitis: a multi-omics Mendelian randomization study.","volume":"22","author":"Dai","year":"2024","journal-title":"J Transl Med"},{"key":"R110-20260610","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1016\/j.biopha.2018.10.137","article-title":"Ankylosing spondylitis and mesenchymal stromal\/stem cell therapy: a new therapeutic approach.","volume":"109","author":"Abdolmohammadi","year":"2019","journal-title":"Biomed Pharmacother"},{"key":"R111-20260610","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1007\/s12015-025-10857-0","article-title":"Applications of gene editing and nanotechnology in stem cell-based therapies for human diseases.","volume":"21","author":"Bolideei","year":"2025","journal-title":"Stem Cell Rev Rep"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000044201","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T10:01:50Z","timestamp":1781085710000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000044201"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,23]]},"references-count":111,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000044201","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,23]]},"assertion":[{"value":"2025-03-19","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-08-10","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}